Running head: STATINS AND KIDNEY FAILURE

Statins and Kidney Failure

Rebekah Pemberton

A Senior Thesis submitted in partial fulfillment
of the requirements for graduation
in the Honors Program
Liberty University
Spring 2015

1

STATINS AND KIDNEY FAILURE

Acceptance of Senior Honors Thesis
This Senior Honors Thesis is accepted in partial
fulfillment of the requirements for graduation from the
Honors Program of Liberty University.

______________________________
Lynne Sanders, Ed.D, MSN, RN, CNE
Thesis Chair

______________________________
Kathryn Miller, MSN, CNE
Committee Member

______________________________
Carl Curtis, Ph.D.
Committee Member

______________________________
Marilyn Gadomski, Ph.D.
Assistant Honors Director

______________________________
Date

2

STATINS AND KIDNEY FAILURE

3
Abstract

Use of the HMG-CoA Reductase Inhibitors, also known as statins, in patients with renal
dysfunction is laden with controversy. Studies on statin use in renal patients have given
varying reports. Some research has indicated that these medications may exacerbate
existing renal dysfunction and induce further progression of renal disease. Furthermore,
some researchers have suggested statins may actually cause some cases of renal
dysfunction through the effects of rhabdomyolysis, acute interstitial nephritis, or
necrotizing immune-mediated myopathy, while other researchers have asserted that the
statins can have nephroprotective effects. The use of statins is believed to be ineffective
in patients who are already in end-stage renal failure, but the research varies on this point,
as well. There is currently a lack of researched knowledge regarding the safety and
efficacy of HMG-CoA Reductase Inhibitors in patients with renal dysfunction, as well as
the potential causative link between these medications and renal dysfunction.
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Statins and Kidney Failure
According to the latest data from the Centers for Disease Control and Prevention
(CDC), over 20 million people in the United States (U.S.) have chronic kidney disease
(CKD); this accounts for more than 10% of the U.S.’s adult population (Centers for
Disease Control and Prevention, 2014b). Many of these individuals are likely to have
elevated serum cholesterol levels, causing CKD patients to have higher rates of
cardiovascular disease (Elliott, McCaughan & Fogarty, 2014). One of the most common
pharmacological treatments for patients with elevated cholesterol levels is the use of
HMG-CoA Reductase Inhibitors, also known as statin drugs. Catapano (2012, Abstract)
named the statins as “the most widely prescribed therapeutic class of drugs worldwide.”
Recent national statistics indicate that the use of statins in the U.S. is apparently
increasing as more Americans are developing hypercholesterolemia and require
pharmacological treatment (Centers for Disease Control and Prevention, 2014a).
Statins’ Nephrotoxic Effects
Statins generally have few adverse effects; however, they can cause myotoxicity
in some patients, leading to muscle breakdown. According to a systematic review
published by Ganga, Slim and Thompson (2014), about 10-25% of patients treated with
statins in clinical practice develop muscle problems. As muscle fibers break down, a
byproduct known as myoglobin travels to the renal system where the kidneys attempt to
process and eliminate the myoglobin. The healthy renal system, unprepared for
myoglobin’s large protein structure, may lose its ability to function in response to
myoglobin accumulation in the renal glomeruli. For a renal system that is already
damaged, as in someone with CKD, the kidneys may become even further damaged and
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the CKD may progress to a later stage, possibly necessitating the use of renal
replacement therapy (RRT), such as hemodialysis (HD), peritoneal dialysis (PD), or a
renal transplant (Olyaei, Greer, Santos & Rueda, 2011). According to Auer, Sinzinger,
Franklin and Berent (2014), renal compromise is the most common form of organ
damage related to statin-induced myopathy.
The most severe form of statin-related myotoxicity is rhabdomyolysis. Mendes,
Robles and Mathur (2014) published a comprehensive review of 112 cases of
rhabdomyolysis, asserting that statin-induced rhabdomyolysis is generally rare in most of
the general population, and it causes approximately 0.3-13.5 cases per 1,000,000 statin
prescriptions; however, other forms of toxicity are less rare and can result in organ
damage. Olyaei et al. (2011) examined case studies of kidney transplant patients and
patients with CKD who received statins, and they found that patients with preexisting
renal problems such as CKD actually have a much higher risk of developing statinrelated myalgia, myopathy, and rhabdomyolysis than those in the general population.
Although myopathy is a known side effect of the statin drugs, and such myopathy
may lead to renal dysfunction, there is limited research on the incidence of statin-caused
renal dysfunction related to myopathies other than rhabdomyolysis. Ironically, some
research has indicated statins might have nephroprotective effects; for this reason, statin
therapy is sometimes prescribed for patients who have an increased risk for acute kidney
injury (AKI), a condition of renal insufficiency that can lead to renal failure and CKD.
Statin use in patients who already have renal dysfunction is also controversial due to a
lack of ample research on the safety and efficacy of statin use in patients who already
have renal dysfunction with or without the need for dialysis.
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Intended Effects of Statins
Elevated serum cholesterol levels have long been associated with an increased
risk for cardiovascular events, due to cholesterol’s role in atherosclerosis, a disease
process in which artery walls thicken in response to lipid accumulation and inflammatory
processes within the vessels. Although dietary interventions and lifestyle modifications
are generally the recommended treatment method for hypercholesterolemia, sometimes,
hypercholesterolemia is very severe, or it does not respond effectively to these
interventions alone, so patients may use pharmacological therapy to treat their
hypercholesterolemia. The first-line pharmacological therapy for elevated cholesterol is
treatment with a statin drug (Catapano, 2012). According to the CDC (2014b), a growing
number of people in the United States are developing hypercholesterolemia, and
consequently use statins in an attempt to control their cholesterol levels.
There are two ways cholesterol enters the bloodstream: through dietary,
exogenous cholesterol and through endogenous cholesterol produced by the liver, which
constitutes the greater part of serum cholesterol. Since cholesterol is a lipid, it cannot
move freely in the blood. Instead, lipoproteins cover the cholesterol molecules within a
phospholipid layer, so the cholesterol can then travel through the bloodstream to the body
cells where it impacts essential cellular functions. High-density lipoproteins (HDLs) are a
type of lipoprotein that consists of a high protein percentage and a low percentage of
cholesterol, whereas low-density lipoproteins (LDLs) contain a minor protein component
with a high cholesterol percentage. Due to their high percentage of cholesterol, LDLs are
strongly involved in coronary atherosclerosis; thus, lowering LDL levels may actually
reverse atherosclerotic changes in some people’s vessels. In contrast to LDLs, HDLs
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function to remove LDL-carried cholesterol from body cells and carry it back to the liver,
where it is metabolized and eventually eliminated from the body; thus, HDLs have
protective effects against atherosclerosis (Mani et al., 2014).
The effects of the statin drugs derive from the statins’ inhibition of an enzyme
known as HMG-CoA Reductase (3-hydroxy-3-methylglutaryl coenzyme A Reductase),
which catalyzes an essential reaction in hepatic cholesterol synthesis. Although HMGCoA Reductase inhibition actually increases the hepatic synthesis of HMG-CoA
Reductase, it also causes hepatocytes to synthesize more LDL receptors, which then bind
to LDL, and remove it from the bloodstream. Mani et al. (2014) published a retrospective
analysis of 2,566 patients receiving statins, which suggested that by inhibiting HMGCoA Reductase, the statin drugs might reduce cholesterol synthesis and thereby decrease
atherosclerotic plaque development within blood vessels. Since cholesterol is an
independent risk factor for major cardiovascular events and mortality, statin therapy is a
respected form of preventive treatment for cardiovascular disease (Centers for Disease
Control and Prevention, 2014a).
A recent study by Lee et al. (2011) examined atherectomy specimens from 22
patients with unstable angina and 21 patients with stable angina that had undergone
surgery due to de novo coronary artery lesions. The researchers tested the specimens for
the presence of antibodies specific to HMG-CoA Reductase, and they found that patients
with HMG-CoA Reductase in these plaques were much more likely to have unstable
versus stable angina. The study revealed that when HMG-CoA Reductase is present in
atherosclerotic plaques, this enzyme might contribute to additional cholesterol synthesis
and make these plaques more unstable and likely to rupture. Plaque rupture often leads to
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adverse outcomes due to myocardial infarction (MI), cerebrovascular accident (CVA),
and other adverse cardiovascular events (Lee et al., 2011).
Controversy over Statin’s Effects on the Kidneys
Current research concerning statins’ effects on the renal system is rather
inconsistent, since some studies have asserted that statins can protect against renal injury
and AKI, whereas others have attributed cases of AKI and advanced CKD to myopathies
caused by statins (Kostapanos, Milionis & Elisaf, 2010). Statin use in patients who have
preexisting renal dysfunction prior to statin therapy is particularly controversial. Ahmad
(2014) asserted that although rhabdomyolysis in the general population is somewhat rare,
the incidence of rhabdomyolysis in patients with CKD is much higher than in the general
population and the myopathy from statin use is also relatively common; such myopathy
can also progress CKD in the same way that rhabdomyolysis can progress CKD. At the
same time, statins’ effects in lowering serum cholesterol and preventing atherosclerotic
plaque build-up might benefit the kidneys and invalidate concerns about statins’ risk.
Statin therapy for patients with CKD requires careful consideration into their risks and
benefits to the kidneys.
The statin drugs may potentiate multiple effects on the kidney. Perhaps, the most
intriguing aspect of these medications and their effects on the kidneys is the fact that they
are neither inherently nephrotoxic, nor are they inherently nephroprotective. Part of the
problem with determining the full extent of statin-caused renal damage derives from the
fact that there are several different forms of muscle problems that relate to statin therapy,
and rhabdomyolysis is only one of these. In a recent article discussing statin intolerance
due to myopathies or high creatine kinase levels, Ahmad (2014) admitted that there is
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still not a standardized criterion for describing or diagnosing statin intolerance. Auer et
al. (2014) also discussed the discrepancies in clinical research studies and everyday
practice, saying that inconsistent definitions or exclusion criteria may explain the
inconsistent data. They described statin myopathy as being an entity with no clearly
agree-upon definition (Auer et al., 2014).
Statin-Induced Renal Damage
Research has indicated that statins may be directly responsible for potentiating
and progressing some cases of renal dysfunction. The exact mechanism by which they
may exert nephrotoxic effects is unclear, however. Table 1 shows some relevant studies,
detailing the methods used to collect the data, as well as the study findings.
Table 1
Study/
Year

Data
analysis
by
Murugan
et al./
2012

Studies that suggest statins may contribute to all types of renal insufficiency
Population

Intervention/
Methods

Comparison

Outcome

Time

Patients
hospitalize
d with
community
-acquired
pneumonia

Multicenter,
prospective
observational
inception cohort
study

1,423
patients did
not receive
statin
therapy
prior to
hospitalizati
on for
pneumonia

Patients who used
statins prior to
hospitalization had
an increased
incidence of AKI

Oneyear
followup
period

4,134
participants
reported
having
hypertensio
n, a known
CKD risk
factor

Statin usage was an
independent risk
factor for the
presence of CKD

Twoyear
followup
period

N=1,836;
≥18 years
Data
analysis
by Zhang
et al./
2009

413 patients
received statin
therapy prior to
hospitalization
for pneumonia
Cross-sectional,
multivariate
analysis

Saarland
inhabitants
who
participated
in the
848 participants
ESTHER
reported regular
Study from statin usage
July 2000
to
December

3,977
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PLANET
I/ 2006

N=9,806;
50-74
years;
55%
female
Patients
with
urinary
protein/cre
atinine
ratios of
500-5,000
mg/g and a
fasting
LDL
cholesterol
of ≥90
mg/dL
N=325

10
participants
reported
having
diagnosed
hyperlipide
mia

Randomized,
prospective
study
Patients in the
experimental
group received
80 mg
atorvastatin per
day

Patients in
the control
groups
either
received 40
mg
rousvastatin
per day or
10 mg
rosuvastatin
per day

Atorvastatin use
reduced proteinuria
by approximately
20%, but there was
no effect on the rate
of decline in
glomerular filtration
rate (GFR)

52week
followup
period

Rosuvastatin did not
affect proteinuria,
but it decreased
GFR by 8
mL/minute every
year
Renal adverse
reactions were
higher with
rousvastatin use

As demonstrated in Table 1, Murugan et al. (2012) studied a large cohort of 1836
patients with community-acquired pneumonia. Of the 1836 total patients studied, 413
patients received a statin prior to their hospitalization. The purpose of the study was to
determine if statin use decreased patients’ risk for pneumonia-induced AKI as well as
examining whether one-year and cause-specific mortality in AKI patients decreased with
statin therapy. As described in Table 1, the study revealed that the 413 patients who took
a statin before coming to the hospital did not have a lower risk for AKI; however, if they
did develop AKI, they had a slightly lower risk of death at one year. One-third of the
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deaths in AKI patients related to cardiovascular disease. The researchers concluded that
statin usage did not decrease the risk for AKI and did not correlate with a decreased risk
of death at one year (Murugan et al., 2012).
Another study by Zhang et al. (2009) that analyzed multiple variables including
older age, cardiovascular history, DM and the use of statins concluded that statin use may
increase the risk of CKD. The researchers included the analysis of studies such as the
ESTHER Study (Epidemiologische Studie zu Chancen der Verhuetung, Frueherennung
und optimierten Therapie chronischer Erkrankungen in der aelteren Bevoelkerung),
which collected data on a large sample of patients who ranged in age from 50 to 74 years
old and had CKD. The study revealed statistically significant increases in the incidence of
CKD for patients who had formerly taken statins, as Table 1 further describes. The
researchers therefore advised older adults to cautiously consider the effects of these
medications on their renal systems (Zhang et al., 2009).
In 2013, Olyaei et al. conducted a literature review of studies that analyzed statin
use in patients with CKD and end-stage renal disease (ESRD). They discussed several
newly published studies including Prospective Evaluation of Proteinuria and Renal
Function in Diabetic Patients with Progressive Renal Disease PLANET I and PLANET
II. In these studies groups of 325 and 220 patients respectively were selected based on the
presence of a urinary protein/creatinine ratio of 500 to 5,000 milligrams (mg) per gram
and a fasting LDL-cholesterol level of greater than or equal to 90 mg/dL. Participants
were divided into randomized groups that either received daily 80 mg doses of
atorvastatin, daily 10 mg doses of rosuvastatin, or daily 40 mg doses of rousvastatin. The
study revealed that atorvastatin therapy generally decreased participants’ incidence of

STATINS AND KIDNEY FAILURE

12

proteinuria; however, atorvastatin therapy did not affect the rate of GFR decline. In
contrast, rosuvastatin causes GFR to decline by 8 milliliters per minute each year, while
having no effect on urinary excretion of protein. Based on these results as shown in Table
1, Olyaei et al. (2013) concluded that statin therapy for patients with CKD is complex
and may not be as safe or effective as statin therapy in non-CKD patients.
Possible Nephroprotective Effects
In contrast to the studies that emphasize the potential nephrotoxic effects of the
statins, some studies have indicated that statin medications may be useful in preventing or
slowing renal dysfunction and may even have nephroprotective effects, especially when
used before surgery. Surgical patients have an increased risk for developing AKI due to
fluid loss as well as pharmacologic therapy that may be used during surgery. On some
occasions, healthcare providers have chosen to give statin medications in an attempt to
decrease this risk (Lee et al., 2011). The exact mechanism of nephroprotection is not
clear; however, several clinical trials have shown a possible benefit to such prophylactic
therapy. Below, Table 2 outlines various trial findings, describing the data collection
methods, as well as the results.
Table 2 Studies that suggest statins have nephroprotective effects
Study/
Year

Population

Intervention/
Methods

Data
analysis
by Layton
et al./
2013

Patients
who
underwent
CABG
surgery

Retrospective
cohort study of
CABG patients

N=17,077;
52.5-76.4
years;

Comparison

Control
group of
13,992
patients did
3,085 patients
not receive
received statins statins prior
<20 days prior
to nonto non-emergent emergent
CABG surgery CABG

Outcome

Time

Statin use prior to
non-emergent
CABG was
consistently linked
with a decreased
risk of AKI

Data
was
collecte
d on a
ten-year
period
from
2000 to
2010
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33%
female
Data
analysis
by
Brunelli et
al./
2012

Patients
who
underwent
major open
abdominal,
cardiac,
thoracic, or
vascular
procedures
N=78,100;
43.5-75.3
years;
45.6%
female

Data
analysis
by Luk et
al./
2010

Data
analysis
by Zhang
et al./
2011

Chinese
patients
with type 2
diabetes
recruited
between
1996 and
2005
N=5,264;
45-66
years;
53%
female
Patients
who
underwent
radiocontra
st
procedures
and were
enrolled in
randomized
, controlled
trials

13
surgery

Retrospective
Control
cohort study of group of
surgical patients 67,321
patients did
10,779 patients not receive
received at least statins prior
one dose of
to surgery
atorvastatin,
Fluvastatin,
lovastatin,
pravastatin,
rosuvastatin, or
simvastatin
between
hospital
admission and
surgery
Prospective
3,989
cohort study of patients did
the Hong Kong not receive
Diabetes
statins
Registry

Statin users had an
18-22% reduction in
the development of
AKI within 72 hours
following surgery

Data
was
collecte
d on a
ten-year
period
High-potency statins from
seem to have more
2000 to
protective power
2010
against AKI

Statin users had a
68% reduction in
the incidence of
renal dysfunction

2.777.04
year
followup
period

Statin use was not
associated with a
significant decrease
in the incidence of
contrast-induced
nephropathy

2.7
days to
10.6
month
pretreat
ment
period;
Onemonth
followup

1,275 patients
received statins

Meta-analysis
of randomized,
controlled trials
370 patients
received statins
prior to contrast
procedures

381 patients
did not
receive
statins prior
to their
contrast
procedures

Some evidence
exists that statin
pretreatment may
slightly decrease
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14
serum creatinine
levels in patients
undergoing
radiocontrast
procedures

period

The findings of a study conducted by Layton et al. (2013), outlined in Table 2,
supported the use of statins prior to coronary artery bypass grafting (CABG) surgery,
since these medications may decrease the risk of AKI postoperatively. For this study, the
researchers analyzed health care claims from large, employer-based and Medicare
databases for the presence of a protective impact on the kidneys from statin therapy.
Patients who were undergoing CABG surgery were selected as the sample group. The
researchers found a very significant decrease in the incidence of AKI for patients who
underwent statin therapy and consequently asserted that statins can protect the renal
system for patients undergoing CABG surgery. Layton et al. (2013) theorized that the
results would probably be similar for other types of surgery.
Brunelli et al. (2012) published the findings of their retrospective analysis of a
cohort of 98,939 patients, 10,779 of whom received preoperative statin therapy before
cardiac, thoracic, or vascular surgery. As shown in Table 2, this preoperative statin use
was particularly advantageous in preventing renal damage in patients who underwent
vascular surgery and least advantageous to patients who underwent cardiac surgery.
Brunelli et al. (2012) therefore concluded that preoperative statin use might have the
potential to decrease the incidence of AKI.
Luk et al. (2010) performed a prospective cohort study on the effects of statin use
for 5,264 patients in China with type II diabetes mellitus (DM) over a nine-year period.
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As outlined in Table 2, the study disclosed that the incidence of renal dysfunction
decreased by 68% in patients who received statin therapy. The researchers consequently
asserted that statin use might lower the risk of renal dysfunction and nephropathy related
to type II DM (Luk et al., 2010).
In an attempt to study the incidence of contrast-induced nephropathy in statin
users, Zhang et al. (2011) conducted a meta-analysis of available data on randomized,
controlled trials of patients who received statin therapy prior to radiocontrast studies. The
results of the four selected trials, displayed in Table 2, revealed a lack of evidence that
statin pretreatment before contrast procedures could decrease the incidence of contrastinduced nephropathy. There was, however, some evidence that statin therapy might cause
a slight decrease in serum creatinine levels. The researchers concluded that statins may
help prevent nephropathy related to contrast dye used in radio-contrast studies, although
more research is necessary before this practice is considered evidence-based.
Statin Use in Renal Patients
The initiation of statin therapy in patients with pre-existing renal dysfunction is
laden with controversy. Several recent studies have led researchers to theorize that statins
are actually not always very effective in lowering lipids in patients with all stages of
CKD, including both dialysis patients and patients who do not require dialysis. Some
studies have also concluded that since the nature of statin therapy requires that it be used
for chronic treatment of hypercholesterolemia, the risks may not outweigh the benefits
for patients with preexisting renal problems because long-term statin therapy increases
the risks of myopathy leading to renal dysfunction.
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A meta-analysis of randomized, controlled studies by Nikolic et al. (2013) found
that the cardiovascular benefits of statins, which include influencing C-reactive protein
levels, require that long-term therapy be maintained; unfortunately, such long-term
therapy also significantly increases the risk of myopathy, which can lead to renal
dysfunction, AKI, and possibly CKD. Nikolic et al. (2013) analyzed trials involving CKD
patients who received statin therapy from 1966 to May 2012. Their final review
incorporated the results of sixteen trials and 3,594 subjects. The trial findings showed a
statistically significant decrease in total cholesterol, triglycerides, and LDL levels for
early-stage CKD patients who took statins. Patients who took statins for a longer duration
had even greater benefits related to the prolonged therapy. Dialysis patients had less
significant decreases in the levels of these independent cardiovascular risk factors. The
researchers stated that for these patients, the magnitude of total cholesterol and LDL was
lower and triglycerides actually had a modest increase. When patients received short-term
statin therapy, they were more likely to have increased HDL levels with an average
increase of 0.7 mg/dL. In contrast, patients who received long-term statin therapy were
likely to experience an average reduction of 2.4 mg/dL.
As a result of their meta-analysis, Nikolic et al. (2013) concluded that patients
who are not on dialysis are likely to experience significant lipid profile changes, whereas
patients on dialysis may not experience statistically significant lipid profile changes; nondialysis patients also generally experience improved outcomes related to longer-term
therapy, whereas dialysis patients actually have surprisingly decreased effectiveness
related to longer-term therapy; perhaps this means that dialysis patients who wish to
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receive the cardiovascular benefits of statin therapy should only receive the statins for a
very short duration (Nikolic et al., 2013).
While controversy still prevails over the effectiveness of statins at lowering lipids,
there is a small amount of recent research that seems to indicate that in some cases of
renal dysfunction, statins may not cause a therapeutic decrease in the risk for
cardiovascular events, even if they may lower lipids. These studies raise the question of
whether statin therapy is worthwhile, since it may increase the patient’s risk of
progressive renal dysfunction without truly having a therapeutic benefit on the patient’s
cardiovascular health.
Natsuaki et al. (2012) detailed the results of the CREDO-Kyoto PCI/CABG
Registry Cohort-2 study, which indicated statin usage does not significantly decrease the
risk for major adverse cardiovascular events in patients with severe CKD. Statin use
consistently related to a decreased risk of AKI, defined using serum creatinine changes as
outlined by Acute Kidney Injury Network and Risk-Injury-Failure staging systems, and
on the need for RRT.
Olyaei, Greer, Santos, & Rueda (2011) completed a meta-analysis of the relevant
literature that included the results of primary intervention studies and secondary
intervention studies. Studies included the Study of Heart and Renal Protection (SHARP
trial), described in Table 3, and the Incremental Decrease in Endpoints through
Aggressive Lipid Lowering (IDEAL) trial, also outlined in Table 3. A Study to Evaluate
the Use of Rosuvastatin in Subjects on Regular Hemodialysis (AURORA trial), which is
outlined in Table 4, was also analyzed. Olyaei et al. (2011) asserted that patients in all
stages of CKD are more likely to develop myalgia, myopathy and rhabdomyolysis from
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statin therapy than patients who do not have some form of renal dysfunction; this study
also concluded that CKD patients who are taking statins to lower their cholesterol should
receive the lowest possible dose (Olyaei et al., 2011).
The question remains: if myopathy and renal damage are valid concerns for those
taking statins, how can healthcare providers advocate for their patients’ safety? In a
recent article depicting their retrospective research study, Sai et al. (2013) advocated a
standardized detection algorithm, which would allow physicians and other healthcare
providers to detect statin-induced myopathy (SIM) based on the electronic medical record
(EMR). The researchers collected data from the EMRs of 5,109 patients who had taken
statins. They monitored the EMRs for changes including increased creatine kinase (CK)
and were able to accurately detect five cases of suspected SIM (Sai et al., 2013). Such an
algorithm may make it possible for conditions such as rhabdomyolysis to be diagnosed
earlier than they would be otherwise, so they can be treated earlier and cause less longterm damage to the renal system.
Possible Effectiveness of Statin Therapy in Renal Patients
Some studies of statin therapy in renal patients suggest that the benefits of statin
therapy are significant enough to warrant statin use even in patients with various types of
renal dysfunction. Among these, the Study of Heart and Renal Protection (SHARP trial)
and Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL
trial) stand out as the most prominent clinical trials. The IDEAL trial, in particular, which
was published in 2010, is still held up as a relevant research study in the discussion of
statin therapy in renal patients. Below, Table 3 outlines the results of various studies,
describing the data collection methods and the findings.
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Table 3 Studies that suggest the effectiveness of statins in lowering cardiovascular risk for
patients with renal dysfunction
Study/
Year

Population

Intervention/
Methods

Comparison

Outcome

Time

The
SHARP
trial/
2011

Patients with
preexisting CKD
and no known
history of MI or
coronary
revascularization

Randomized,
double-blind
study

Control
group of
4,620
patients
received a
matching
placebo

The experimental
group had a 17%
reduction in major
atherosclerotic
events

4-9
year
follow
-up
period

Comparison
group of
4,449
patients
received 20
mg
simvastatin
daily

Atorvastatin users
had lower mean
LDL levels than
simvastatin users

Control
group of
7,478
patients did
not receive
statin
therapy

Statin users without
CKD and with mild
CKD had a
significantly
decreased incidence
of major adverse
cardiovascular
events

33% of total
study population
was receiving
maintenance HD
or PD

The
IDEAL
trial/
2005

N=9,270;
40-70+ years;
37% female
Patients with
history of MI
who underwent
statin therapy for
elevated serum
cholesterol levels
between 1999
and 2005
N=8,888;
52-71 years;
19% female

The
CREDO
-Kyoto
PCI/CA
BG
Registry
Cohort2/
2012

Patients with
advanced CKD
undergoing
coronary
revascularization
N=14,706;
53-75 years;
28% female

4,650
patients
received a
combination
of
simvastatin
plus
ezetimibe

Open-label,
blinded, endpoint,
randomized,
controlled
trial
4,439
patients
received 80
mg
atorvastatin
daily
Retrospectiv
e cohort
study
7,228
patients
received
statin therapy

There were no
statistically
significant
differences between
the results of
participants on
dialysis and those
who were not on
dialysis

898 atorvastatin
users experienced a
coronary event
during therapy,
versus 1,059
simvastatin users

There was no
significant risk

Media
n 4.8year
follow
-up
period

6991,245
day
follow
-up
period
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The
SWEDE
HEART
Registry
Study/
2011

Survivors of MI
178 patients
received dialysis
prior to
admission

Patients
received
statins at
discharge
from MIhospitalizatio
n

20

Control
group of
patients did
not receive
statins at
discharge

decrease in patients
with severe CKD or
HD patients
Statin users with
stages 2-4 of renal
insufficiency had
improved one-year
survival rates

Follo
w-up
period

N=42,814
Baigent et al. (2011) detailed the findings of the randomized placebo-controlled
study known as the SHARP trial. The SHARP trial studied 9,270 patients with CKD with
no known history of MI or coronary revascularization who received either daily doses of
simvastatin 20 mg plus ezetimibe 10 mg or a matching placebo. 4,650 patients received
the combination-drug, whereas 4,620 patients received a placebo. Researchers followed
up with these patients after an average period of 4.9 years since the beginning of the trial
to monitor for the occurrence of a first-time major atherosclerotic event, which was
predefined by the study as a nonfatal myocardial infarction or coronary death, nonhemorrhagic stroke, or any arterial revascularization procedure. Patients who received the
simvastatin-ezetimibe combination experienced a 17% proportional reduction in major
atherosclerotic events. Only 131 of the patients who took the simvastatin-ezetimibe
combination medication experienced non-hemorrhagic stroke, as compared to 174 of the
patients who took the placebo. Likewise, only 284 patients who received simvastatinezetimibe therapy required arterial revascularization procedures as opposed to 352 of the
patients who received the placebo. Baigent et al. (2011) therefore concluded simvastatin
effectively reduced the risk of cardiovascular events in CKD patients when paired with
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ezetimibe; these researchers therefore recommend the use of this particular statin
combination drug for lowering cholesterol in patients with CKD.
The findings from the SHARP trial are highly respected in the medical
community and have integrated themselves in many cases into evidence-based practice
(EBP) related to statin therapy. A systematic review and meta-analysis by Palmer et al.
(2012) asserted that SHARP had a low risk of reporting bias, which reaffirms its
credibility. In their discussion, however, Palmer et al. pointed out that dialysis patients
who receive statins do not have a clear clinical reduction in major cardiovascular events,
a fact that appears to contradict SHARP’s findings (Palmer et al., 2012).
Numerous articles and reviews have been published on the findings from the
SHARP trial, with different conclusions made in each case. Auer et al. (2014) recently
analyzed the findings from the SHARP trial and came to the conclusion that there is a
need for further research regarding statin-caused myopathy. They reiterated the concern
that statin-related myopathy and renal dysfunction will only increase as more and more
people receive statin therapy (Auer et al., 2014). In contrast, Jenkins and Goldsmith
(2012) published an analysis of the SHARP trial that concluded the benefits of statin
therapy warrant that CKD patients should undergo prophylactic statin therapy, regardless
of whether their LDL cholesterol levels are high, since CKD patients are inherently
predisposed to atherosclerosis and cardiovascular events. An analysis of the SHARP trial
by Holme et al. (2011) suggested that in CKD patients statin therapy may decrease risk
for some particular types of cardiovascular events, while not decreasing the risk of major
coronary events; in contrast, statin therapy in non-CKD patients decreases the risk for
major coronary events, as well as all other cardiovascular events except stroke.
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Bae et al. (2012) performed a retrospective cohort study that included the analysis
of 12,636 patients with acute myocardial infarction (AMI) in the Korea AMI Registry
from 2005 to 2008. Of the patients in the registry, 93% had coronary angiography and
91% of the patients who had coronary angiography had percutaneous coronary
intervention (PCI) as well. This study revealed that patients who took beta-blockers,
angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers
with statins had a significantly lower risk of major adverse cardiac events in the onemonth and one-year follow-up periods. According to the findings of this study, statins
might effectively decrease risk for major adverse cardiovascular events; this study also
asserted that patients’ estimated glomerular filtration rate (eGFR) can be used as an
indicator of their risk for mortality related to cardiovascular events (Bae et al., 2012).
In 2011, Szummer et al. completed a retrospective cohort study that confirmed
statin therapy after a MI is effective in decreasing the incidence of death from
cardiovascular events and in protecting against renal dysfunction and failure from AKI
and CKD. The researchers analyzed data from the national SWEDEHEART Registry
related to 42,814 consecutive MI survivors who did not take statin therapy prior to
hospitalization for their MIs. They found that patients in the early stages of CKD had a
significant decrease in their overall mortality. The study published by Szummer et al.
(2011) also indicated that statins might have the potential for improving the one-year
survival rate of patients who are in stages 2-4 of kidney failure.
Lim et al. (2012) conducted a study that supported the use of statins in patients
with various types of renal dysfunction including CKD, since this study found statin
therapy improved outcomes in CKD patients. The researchers studied a retrospective
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cohort of 12,853 patients with AMI. They divided the cohort into four different groups:
those who did not have any form of renal dysfunction and received statins, those who
neither received statin therapy nor had renal dysfunction, those who both received statin
therapy and had renal dysfunction, and those who had renal dysfunction but did not have
renal dysfunction. The researchers then analyzed the separate groups for the primary end
points of death and hospitalization complications, as well as secondary end points of
MACE during the one-year post-AMI follow-up period. The study revealed that both
patients with renal dysfunction and patients who did not have renal dysfunction
experienced a decrease in the incidence of MACE during the follow-up period. Lim et al.
(2012) therefore concluded that statin therapy could be beneficial for both patients with
and without renal dysfunction. One limitation of this study is the fact that renal
dysfunction was not clearly defined and may have only included patients in the very early
stages of CKD, which would have impacted the results of the study.
A systematic review and meta-analysis of various studies with CKD patients who
took statins revealed some interesting findings. Palmer et al. (2012) discussed the
findings of trials such as SHARP, AURORA, and 4D (Deutsche Diabetes Dialyse
Studie). The researchers concluded that based on the latest research findings, statin
therapy in CKD patients who are in the early stages of the disease and do not yet require
dialysis can reduce cardiovascular events and mortality (Palmer et al., 2012).
Most of the reviewed studies agreed that although statin use may potentially be
helpful for patients in stages 2-4 of CKD, patients on dialysis or other forms of renal
replacement therapy (RRT) may derive little to no cardiovascular benefit from statin use
and may in fact do themselves more harm than good.
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Possible Ineffectiveness of Statin Therapy in Renal Patients
Although some research seems to support statin therapy’s efficacy and safety for
patients with renal impairment, other studies are not so supportive. At any rate, the
overwhelming majority of studies have suggested that patients with ESRD, and
particularly those on HD, might not experience the desired effects of these drugs. Also,
the risks of causing a preexisting renal dysfunction to progress further may outweigh the
benefits of statin therapy for patients who may not even have ESRD but have some level
of renal impairment. Below, Table 4 describes the various studies that suggest statin
therapy may be ineffective in patients with renal dysfunction, as well as the datacollecting methods and study outcomes.
Table 4 Studies that suggest statins are ineffective in lowering cardiovascular risk for
patients with renal dysfunction
Study/
Year

Population

Intervention/
Methods

Comparison

Outcome

Time

The
AURORA
trial/
2009

Patients
with ESRD
who had
received
routine HD
for at least
three
months

Randomized,
double-blinded
placebocontrolled
multicenter trial
study

Patients in
the control
group
received a
placebo

Experimental group
had 43% reduction in
LDL-C level and
27% reduction in
total cholesterol
levels

Threeyear
follow
-up
period

Patients in the
experimental
N=2,776
group received
50-80 years rosuvastatin as
38%
primary
female
prevention
against a major
cardiovascular
event

No statistically
significant decrease
in the incidence of a
major cardiovascular
event (defined as
nonfatal MI, nonfatal
stroke, or death
related to
cardiovascular
disease)
396 rosuvastatin
users had a major

STATINS AND KIDNEY FAILURE

25
cardiovascular event;
408 placebo users
had a major
cardiovascular event

The 4D
Study
(Deutsche
Diabetes
Dialyse
Studie)/
2005

Patients
with type 2
diabetes
mellitus
who had
received
HD for
more than
two years
Baseline
cholesterol
was
between 80
and 90

Randomized,
multi-centered,
double-blinded,
placebocontrolled
prospective
study

636 patients
received a
placebo

There was no
significant reduction
in the risk of major
cardiovascular events

Twoyear
follow
-up
period

619 patients
received
atorvastatin

N=1,255
Risks versus Benefits of Statin Use in Renal Patients
Much debate exists regarding the safety and efficacy of the statin HMG-CoA
Reductase Inhibiting medications in relation to the kidneys. An issue of particular
concern is the question of whether these medications may potentially protect the kidneys
from damage and thereby slow the progression of CKD, possibly increasing longevity.
Another area of ambiguity is that of the effectiveness of these medications in lowering
cholesterol and preventing adverse cardiovascular events for patients with various forms
of renal dysfunction, including AKI and CKD. Based on the evidence that is currently
available, it is safe to say that statin usage may have limited safety and efficacy in
treating hyperlipidemia in patients with renal dysfunction
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Ethical Considerations
Although the researchers obtained informed consent before conducting the study,
the SHARP and AURORA trials, like so many other trials, raise several ethical
considerations; namely, is it ethical for researchers to experiment with patients’ lives by
giving them a placebo–and exempting them from getting what is more likely an effective
treatment? This question is not an easy one, but the researchers for any study should
consider it before proceeding with the study. Certain study designs may also help
eliminate the ethical dilemma raised by studies that provide participants with a placebo
instead of an equally effective therapy. According to Sullivan (2011), a trial that utilizes
an equally effective medication considered the standard of care instead of a placebo is
called an active-controlled trial. An active-controlled trial would be ethically appropriate
in cases of hypercholesterolemia in which medication is necessary; patients in the control
group would still receive treatment for their hypercholesterolemia while serving as the
comparison for groups receiving the statin medications.
Method
This integrative review incorporated a search of several nursing and medical
databases, including CINAHL and PubMed, for randomized controlled trials and metaanalyses of recent trials. As Table 5 shows, the search used the key words: statins, HMGCoA Reductase Inhibitors, renal insufficiency, AKI, rhabdomyolysis, statin-caused
myopathy, renal failure, and CKD. Phrases paired various types of renal insufficiency
with the two names used to identify the statin drugs: statins and HMG-CoA Reductase
Inhibitors. The most productive searches were those using the phrases: CKD and statins,
CKD and HMG-CoA Reductase Inhibitors, AKI and statins, AKI and HMG-CoA
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Reductase Inhibitors, renal insufficiency and statins, renal insufficiency and HMG-CoA
Reductase Inhibitors, rhabdomyolysis and statins, and rhabdomyolysis and HMG-CoA
Reductase Inhibitors. A total of 563 articles surfaced. Of the articles that surfaced, only
30 articles fit the two-fold selection criteria of patients with CKD who have taken statins
or patients who have taken statins and developed AKI, which later led to increased risk
for CKD.
Table 5 Search Results
Key Search Terms
(2010-2015)

HMG-CoA Reductase
Inhibitor, statin, renal
insufficiency, renal
failure, chronic kidney
disease, acute kidney
injury, statin-caused
myopathy,
rhabdomyolysis

Cochrane
Review

OVID

EBSCO host
(CINAHL;
Nursing &
Allied Health
Collection)

8

224

247

Pub
Med

Total

84

563

Relevant
Articles

30

Study Selection
Studies were selected based on their relevance to the topic of statins and their
relationship to renal impairment and CKD. Studies of patients with CKD who used
statins were included, as were studies of patients with AKI who used statins. Studies of
patients who developed renal insufficiency, AKI, or CKD with a possible relation to the
use of statins were also included. Studies that discussed statin therapy apart from renal
dysfunction were excluded. Studies of statin use in patients who did not have renal
dysfunction, either prior to statin use or related to statin-caused myopathy were excluded
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as well. Studies with a sample size of less than 40 were also excluded. Data extraction
occurred based on articles that depicted the following outcomes: rhabdomyolysis after
statin therapy in CKD patients, myopathy after statin therapy in patients with renal
impairment, AKI incidence related to statin therapy, AKI prevention related to statin
therapy and reduction in cardiovascular disease-related mortality in CKD patients after
statin therapy.
Data Analysis
Studies were analyzed and divided into groups based on whether the findings fit
into one of the following categories: statins having a positive effect on patients’ renal
function, statins having a negative effect on patients’ renal function, statins decreasing
the risk of cardiovascular disease and/or mortality in patients with renal impairment,
statins having no effect on the risk of cardiovascular disease and/or mortality in patients
with renal impairment and statins increasing the risk of cardiovascular disease and/or
mortality in patients with renal impairment. None of the analyzed studies suggest that
statin therapy increases the risk of cardiovascular disease and mortality in patients with
impaired renal function; therefore, this category was not included in the final integrative
review.
Implications for Nursing Practice
An important consideration for nurses is the possibility of a reliable algorithm for
detecting myopathy related to statin use, as discussed earlier. Such a tool may prove very
useful in preventing serious renal damage before it occurs. If an algorithm becomes
available, nurses should learn how to use it in daily practice so they can integrate this
knowledge into their physical assessments of patients receiving statins and hopefully help
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to detect myopathies related to statin usage. Evidence-based practice can incorporate the
use of a warning system in the EMR. An EMR warning system would be easy for nurses
and other healthcare providers to use, while tracking CK levels and perhaps including
renal-specific indicators such as creatinine clearance rate and blood urea nitrogen (BUN).
A well-designed warning system might also incorporate basic laboratory data such as the
complete blood count (CBC) and symptoms of myopathy such as myalgia, nausea and
vomiting, fever, and tachycardia (Sai et al., 2013). With a proper warning system in the
EMR, nurses could play a vital part in monitoring for renal injury and dysfunction while
continuing to carry out their routine patient assessments and interventions. While an
EMR warning system for statin-induced myotoxicity and renal dysfunction has not yet
been extensively developed and implemented, healthcare providers may be able to design
one in the near future that could help prevent needless renal dysfunction and morbidity.
Nurses also have a responsibility to educate patients about the medications they
receive. Patient education should include teaching about the unique impact these
medications may have on individual patients because of personal idiosyncratic factors
such as CKD. Patients with CKD should learn that there are certain inherent risks if they
choose to begin therapy with statin drugs. As shown in this integrative review, patients
with preexisting renal dysfunction who take statin drugs may be more likely to
experience further progression of their already-present renal dysfunction. There does not
appear to be a difference in the impact of various statins on renal function. Although
CKD and renal impairment does not contraindicate the use of statin therapy to treat
hypercholesterolemia, healthcare providers should be prepared to educate these patients
about the risks versus the benefits of statin therapy.
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Patients with renal impairment may also require dosage modification due to their
impaired renal function, and nurses, as the healthcare providers who perform the last
safety check prior to medication administration, need to be aware of this so that they will
know to advocate for their patients and question an inappropriate dose for a patient with
renal impairment. Since the nurses are often the last ones to see a medication’s dosage
before it is given and they are often the ones giving medications such as the statin
medications in the hospital setting, it is important for them to know what the appropriate
dosages are and how they would be modified in the case of renal dysfunction. Nurses
should be aware of the risks of statin use for patients with CKD and other forms of renal
dysfunction and they should be prepared to inform patients with renal dysfunction of
these risks.
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